Edgewise Therapeutics, a clinical-stage cardiovascular biopharmaceutical company, announced its management will participate in two investor events: the Guggenheim Healthcare Innovation Conference on November 10 and the Truist Biopharma Symposium on November 12, 2026. These presentations will be available via webcast and focus on the company's development of novel therapies for heart conditions like hypertrophic cardiomyopathy and heart failure. This exposure could attract investor interest and highlight Edgewise's progress in cardiac muscle treatment innovation.
Edgewise Therapeutics Inc. (EWTX) holds steady at USD 45.04 on Pluang as of Nov 09, 2026 20:14 WIB. The stock shows no change in the last day and trades with a market cap of $4.93 billion. Investors on Pluang typically hold EWTX shares for about 22 days, reflecting moderate trading interest.
Edgewise Therapeutics announced submission of the STRATUS-HCM Phase 3 protocol for EDG-7500, a drug for symptomatic obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). The trial design includes two independent placebo-controlled studies...
Edgewise Therapeutics reported positive Phase 2 results for EDG-7500, a drug targeting hypertrophic cardiomyopathy (HCM), and plans to start a Phase 3 trial by the end of 2026. The company also began dosing patients in a Phase 2 trial for EDG-15400, ...
